3-methoxy-N-methylpyridine-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-methoxy-N-methylpyridine-2-carboxamide
• 化学式: C₈H₁₀N₂O₂
• 分子量: 166.18
• InChiKey: INALAOBLTQRQAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] 3-CHLORO- AND 3-METHOXY-N-METHYL-2-PYRIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF AS ANTICANCER MEDICAMENT<br/>[FR] COMPOSÉ 3-CHLORO ET 3-MÉTHOXY-N-MÉTHYL -2-PYRIDINE-CARBOXAMIDE ET SON APPLICATION EN TANT QUE MÉDICAMENT ANTICANCÉREUX
  申请人：HUNAN NONFERROUS METALS GROUP CHEMBIO PHARMACY CO LTD

  公开号：WO2014040242A1

  公开（公告）日：2014-03-20

  本发明提供了一种抑制VEGFR-2等激酶的式（I）3-氯-及3-甲氧基-N-甲基-2-吡啶酰胺化合物。本发明还提供了式（I）化合物在制备抗癌药物以及治疗VEGFR-2等激酶所介导疾病的药物中的用途。
• REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS
  申请人：Sienna Biopharmaceuticals, Inc.

  公开号：EP3600440A1

  公开（公告）日：2020-02-05
• [EN] REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS<br/>[FR] CONJUGUÉS D'EXPOSITION RÉDUITE MODULANT DES CIBLES THÉRAPEUTIQUES
  申请人：SIENNA BIOPHARMACEUTICALS INC

  公开号：WO2018175340A1

  公开（公告）日：2018-09-27

  Disclosed herein are polymer conjugates comprising an active agent linked to a polymer, wherein the active agent comprises an inhibitor, antagonist, or inverse agonist of a mediator of a therapeutic target associated with a condition, including for example, an ophthalmic condition, a dermatological condition, an inflammatory bowel disease or other gastrointestinal conditions and a respiratory condition. The disclosed polymer conjugates reduce exposure of the active agent at non-target sites.
• [EN] POLYMER CONJUGATE OF MONTESANIB WITH REDUCED EXPOSURE<br/>[FR] CONJUGUÉ POLYMÈRE-MOTESANIB À EXPOSITION RÉDUITE
  申请人：SIENNA BIOPHARMACEUTICALS INC

  公开号：WO2018175301A1

  公开（公告）日：2018-09-27

  Disclosed herein are polymer conjugates, such as SNA-103, comprising an active agent linked to a polymer, wherein the active agent comprises an inhibitor, antagonist, or inverse agonist of a vascular endothelial growth factor receptor (VEGFR), such as montesanib. The disclosed polymer conjugates reduce exposure of the active agent at non-target sites.
• [EN] REDUCED EXPOSURE COMPOSITIONS MODULATING THERAPEUTIC TARGETS<br/>[FR] COMPOSITIONS À EXPOSITION RÉDUITE DE MODULATION DE CIBLES THÉRAPEUTIQUES
  申请人：SIENNA BIOPHARMACEUTICALS INC

  公开号：WO2020023389A1

  公开（公告）日：2020-01-30

  Disclosed herein are polymer conjugates comprising an active agent linked to a polymer, wherein the active agent comprises an inhibitor, antagonist, or inverse agonist of a mediator of a therapeutic target associated with a condition, including for example, an ophthalmic condition, a dermatological condition, an inflammatory bowel disease or other gastrointestinal conditions and a respiratory condition. The disclosed polymer conjugates reduce exposure of the active agent at non-target sites.